* Tarsus Pharmaceuticals Inc TARS.OQ reported a quarterly
adjusted loss of 61 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-1.28. The mean expectation of
nine analysts for the quarter was for a loss of 97 cents per
share. Wall Street expected results to range from $-1.28 to -82
cents per share.
* Revenue rose 2,471.8% to $48.12 million from a year ago;
analysts expected $43.44 million.
* Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 61 cents.
* The company reported a quarterly loss of $23.42 million.
* Tarsus Pharmaceuticals Inc shares had risen by 44.6% this
quarter and gained 134.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is 62.00
This summary was machine generated from LSEG data November 14 at
04:13 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.97 -0.61 Beat
Jun. 30 2024 -0.92 -0.88 Beat
Mar. 31 2024 -1.20 -1.01 Beat
Dec. 31 2023 -1.36 -1.31 Beat